FDA Approves Keryx’s Kidney Disease Drug Ferric Citrate

Drug Industry Daily
A A
Keryx Biopharmaceuticals said it will launch its renal disease drug ferric citrate within 12 weeks, following FDA approval Friday of the product that controls phosphorus levels in dialyzed chronic kidney disease (CKD) patients.

To View This Article:

Login

Subscribe To Drug Industry Daily